Risk reduction for the acquired immunodeficiency syndrome among intravenous drug users

D. C. Des Jarlais, S. R. Friedman, W. Hopkins

Research output: Contribution to journalArticle

Abstract

Intravenous drug users are the second largest risk group for the acquired immunodeficiency syndrome (AIDS) and a bridge to two other groups: children and heterosexual partners. In the absence of effective treatment or vaccines, control of the epidemic among drug users will rely on efforts to reduce needle sharing. However, the traditional image of intravenous drug users leads one to expect little or no risk reduction. We review characteristics of AIDS as a disease that impede efforts at risk reduction among drug users and report on current risk reduction among intravenous drug users in New York City. There has been a sustained increase in the demand for new, unused needles, as shown in the emergence of 'resealed' needles and in interviews with persons selling needles in illicit drug-purchasing areas.

Original languageEnglish (US)
Pages (from-to)755-759
Number of pages5
JournalAnnals of internal medicine
Volume103
Issue number5
StatePublished - 1985
Externally publishedYes

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Risk reduction for the acquired immunodeficiency syndrome among intravenous drug users'. Together they form a unique fingerprint.

  • Cite this